MGD024

A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
130 patients (estimated)
Sponsors
MacroGenics
Tags
Bispecific Antibody, CD123, CD3
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1691
NCT Identifier
NCT05362773

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.